ALS Invest 1 B.V. - 06 Jan 2022 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: 10%+ Owner
Signature: /s/ Felix-Andre von Coerper
Issuer symbol: AMLX
Transactions as of: 06 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 05 May 2022, 16:46:46 UTC
Next filing: 08 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMLX	Common Stock	Conversion of derivative security		+1,129,386			1,129,386	11 Jan 2022	Direct	F1, F2
transaction	AMLX	Common Stock	Conversion of derivative security		+4,826,503	+427%		5,955,889	11 Jan 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMLX	Series A Preferred Stock	Conversion of derivative security	$0	-1,129,386	-100%	$0.000000^*	0	11 Jan 2022	Common Stock	1,129,386		Direct	F1, F2
transaction	AMLX	Series B Preferred Stock	Conversion of derivative security	$0	-4,826,503	-100%	$0.000000^*	0	11 Jan 2022	Common Stock	4,826,503		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.
F2	The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person.